These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19729499)

  • 1. CSF levels of PSA and PSA-ACT complexes in Alzheimer's disease.
    Mulder SD; Heijst JA; Mulder C; Martens F; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
    Ann Clin Biochem; 2009 Nov; 46(Pt 6):477-83. PubMed ID: 19729499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
    DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI
    Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
    Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.
    Rosso SM; van Herpen E; Pijnenburg YA; Schoonenboom NS; Scheltens P; Heutink P; van Swieten JC
    Arch Neurol; 2003 Sep; 60(9):1209-13. PubMed ID: 12975285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
    Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
    Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
    Zhong Z; Ewers M; Teipel S; Bürger K; Wallin A; Blennow K; He P; McAllister C; Hampel H; Shen Y
    Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M
    Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?
    Leoni V; Shafaati M; Salomon A; Kivipelto M; Björkhem I; Wahlund LO
    Neurosci Lett; 2006 Apr 10-17; 397(1-2):83-7. PubMed ID: 16406316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
    Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
    Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease.
    de la Monte SM; Volicer L; Hauser SL; Wands JR
    Ann Neurol; 1992 Dec; 32(6):733-42. PubMed ID: 1471863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
    Grossman M; Farmer J; Leight S; Work M; Moore P; Van Deerlin V; Pratico D; Clark CM; Coslett HB; Chatterjee A; Gee J; Trojanowski JQ; Lee VM
    Ann Neurol; 2005 May; 57(5):721-9. PubMed ID: 15852395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease.
    Lee JW; Namkoong H; Kim HK; Kim S; Hwang DW; Na HR; Ha SA; Kim JR; Kim JW
    BMC Neurol; 2007 Jun; 7():14. PubMed ID: 17565664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
    Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
    Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
    Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
    Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.